SLC5A2 and type 2 diabetes mellitus: In experimental models of both type 1 and type 2 diabetes, treatment with ipragliflozin reduced levels of oxidative stress biomarkers and inflammatory markers in liver and plasma (Tahara et al., 2013), further supporting the premise that SGLT2 inhibition not only improves hyperglycaemia but also diabetes-associated metabolic and inflammatory abnormalities.